Microbiome is currently in the final phase of translating its patented diagnostic tool, IS-pro, into a state-of-the-art commercial molecular diagnostic tool for inflammatory bowel disease (IBD).
IS-pro is the only test of its kind, analysing more than 10,000 bacterial species simultaneously thereby giving insight into the composition and disturbances of complex bacterial communities. Clinically, IS-pro is able to identify the composition of the intestinal microbiota and compares healthy and diseased samples of patients with IBD. Disturbances in bacterial communities can be rapidly identified and therapy can be initiated or adapted accordingly.
IS-pro is tailor-made to the needs of clinical gastroenterologists and will significantly improve the current clinical diagnostics by assisting in diagnosing, monitoring and assessing effectiveness of therapies in IBD patients. IS-pro has been developed through a unique collaboration with the department of gastroenterology of the VUmc, resulting in seamless incorporation in the routine diagnostic cycle. Ultimately, Microbiome aims for the development of:
1. A customer-friendly technology platform that can be extended to a wide range of applications for multiple market segments
2. A diagnostic kit for the IBD market